The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 21, 2025

Filed:

May. 24, 2021
Applicant:

Truebinding, Inc., Foster City, CA (US);

Inventors:

Dongxu Sun, Los Altos, CA (US);

Catherine A. Gordon, Fremont, CA (US);

Ksenya Shchors, San Mateo, CA (US);

Yan Wang, Concord, CA (US);

Tsung-Huang Tsai, San Carlos, CA (US);

Yew Ann Leong, San Francisco, CA (US);

Assignee:

TrueBinding, Inc., Foster City, CA (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2005.12); A61K 39/00 (2005.12); A61K 39/395 (2005.12); A61P 19/04 (2005.12); A61P 31/14 (2005.12); A61P 37/06 (2005.12);
U.S. Cl.
CPC ...
C07K 16/2851 (2012.12); A61K 39/395 (2012.12); A61P 19/04 (2017.12); A61P 31/14 (2017.12); A61P 37/06 (2017.12); A61K 2039/505 (2012.12); C07K 2317/56 (2012.12); C07K 2317/565 (2012.12);
Abstract

Disclosed herein are methods, antibodies, and compositions for disrupting an interaction between Galectin-3 (Gal3) and viral proteins, such as proteins of the SARS-CoV-2 virus or other coronaviruses, or viral-associated host proteins. Further disclosed herein are methods, medicaments, and compositions for the treatment of a disease or a disorder in a subject, such as the treatment of a viral infection, or treatment of a fibrosis, such as lung fibrosis, that develop as a sequela of a viral infection, or cytokine release syndrome. Further disclosed herein are methods, medicaments, and compositions for the treatment of an inflammatory disease or disorder, such as inflammation of the lungs or systemic lupus erythematosus, which may be associated with neutrophil activity, in a subject. Also disclosed herein are pharmaceutical antibody formulations for the treatment of a disease, such as a coronavirus infection.


Find Patent Forward Citations

Loading…